New IBM Research Model Links Muscle Aging to Disease — And Points to New Treatment Targets
Two major research developments reported in the past week are giving the IBM community new reasons for optimism. Together, they deepen our understanding of why IBM happens and point toward fresh treatment approaches that go beyond anything previously available.
A New Laboratory Model for IBM
Dr. Thomas Lloyd and his team at Baylor College of Medicine, funded by The Myositis Association, have created a patient-derived muscle cell model that closely mirrors what happens inside the bodies of people with IBM. This is a significant achievement — until now, studying IBM at the cellular level has been extremely difficult.
The key findings: Muscle cells grown from IBM patients showed clear abnormalities at every stage of development. Genes linked to stress, inflammation, and muscle breakdown were more active than in healthy cells. DNA damage markers were elevated, and the cells had lower levels of important DNA repair proteins. The researchers also found that IBM shares biological pathways with neurodegenerative diseases like Parkinson's and Alzheimer's.
Most importantly, the IBM cells showed strong signs of cellular senescence — a state where cells stop dividing and begin aging in a harmful way. These aging cells produced inflammatory substances that can worsen the disease. This finding opens the door to treatments that target aging cells directly.
The team tested two senolytic drugs (dasatinib and quercetin) on the IBM cells, but they did not significantly reduce signs of aging or inflammation in this model. However, the model itself is the breakthrough — it gives researchers a reliable tool to test future therapies.
"I'm excited that our data show very clear IBM-related features in this new laboratory model," Dr. Lloyd said. "It suggests this can be a useful tool for studying how IBM develops and for testing new treatments."
CAR T-Cell Therapy Trials Show Mixed Results for Myopathies
Meanwhile, data presented at the EULAR 2026 Annual Meeting in London showed early results from the RESET-Myositis trial, which tested a CAR T-cell therapy called rese-cel (formerly CABA-201) in patients with inflammatory myopathies including dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy, and juvenile myositis.
The therapy was well tolerated, with only mild side effects. Among patients with dermatomyositis, 80% achieved moderate improvement by week 16 while off immunosuppressive drugs, and all maintained their response through week 52. However, results were more mixed for antisynthetase syndrome and necrotizing myopathy patients, with some experiencing relapses.
A separate analysis of 50 patients treated with a different CAR T-cell product (zorpo-cel) found that myositis patients had the highest relapse rate at 37.5%, compared to just 3.6% for lupus patients. Researchers believe that long-lived plasma cells not cleared by the therapy may continue producing the autoantibodies that drive flares.
What This Means for IBM Patients
These studies matter because they shift the conversation from "we don't know what causes IBM" to "we can see the mechanisms and we're testing targeted interventions." The new cell model will accelerate drug testing, and the CAR T-cell data — while still early — is mapping out which approaches work and which need refinement for myositis specifically.
For now, exercise remains the only proven management strategy. But the research pipeline is more active than it has ever been, and these findings bring us closer to the day when effective treatments become available.
Tags
Related Reading
- Early Stage Tips — Exercise, energy conservation, and specialist directories
- Bathroom & Toileting — Equipment, bidets, and transfer techniques
- Travel Tips — Airlines, hotels, and emergency preparedness
- General Tips — Insurance, disability benefits, and support groups